Meeting
2021 ASCO Annual Meeting
Phase 1b study of AMG 757, a half-life extended bispecific T-cell engager (HLE BiTE immune-oncology therapy) targeting DLL3, in de novo or treatment emergent neuroendocrine prostate cancer (NEPC).
Authors
Rahul Raj Aggarwal
Univ of California San Francisco, S San Francisco, CA
Rahul Raj Aggarwal , Ana Aparicio , Axel Heidenreich , Shahneen Kaur Sandhu , Yiran Zhang , Mark Salvati , Aditya Shetty , Nooshin Hashemi Sadraei
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Other Prostate, Testicular, or Penile Cancer
Clinical Trial Registration Number
NCT04702737
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS5100)
DOI
10.1200/JCO.2021.39.15_suppl.TPS5100
Abstract #
TPS5100
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
Phase 1b study of tarlatamab, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting DLL3, in de novo or treatment emergent neuroendocrine prostate cancer (NEPC).
First Author: Rahul Raj Aggarwal
Poster
2022 ASCO Annual Meeting
Phase 2 study of tarlatamab, a DLL3-targeting, half life–extended, bispecific T-cell engager (HLE BiTE) immuno-oncology therapy, in relapsed/refractory small cell lung cancer (SCLC).
First Author: Suresh S. Ramalingam
Poster
2020 ASCO Virtual Scientific Program
Phase I study of AMG 757, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting DLL3, in patients with small cell lung cancer (SCLC).
First Author: Taofeek Kunle Owonikoko
Poster
2019 ASCO Annual Meeting
Phase 1 study of AMG 757, a half-life extended bispecific T cell engager (BiTE) antibody construct targeting DLL3, in patients with small cell lung cancer (SCLC).
First Author: Marie-Anne Damiette Smit